CD34+ Transplants for Leukemia and Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2032

Study Completion Date

September 30, 2032

Conditions
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute
Interventions
RADIATION

Total Body Irradiation (TBI)

Hyper-fractioned TBI is administered by a linear accelerator at a dose rate of \< 15 cGy/minute.

DRUG

Thiotepa

Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).

DRUG

Cyclophosphamide

Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m\^2 x 5 if cyclophosphamide is contraindicated

DRUG

Busulfan

Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics

DRUG

Melphalan

Melphalan: 70 mg/m\^2/day x 2

DRUG

Fludarabine

Fludarabine: 25 mg/m\^2/day x 5

Trial Locations (1)

33176

Baptist Health South Florida/Miami Cancer Institute, Miami

All Listed Sponsors
lead

Guenther Koehne

OTHER